

**<http://www.irw-press.com/en/news/biochem-solutions-signs-25m-vitapro-international-ltd-deal.html?isin=US0909651046>**

## **BioChem Solutions signs \$25M VitaPro International Ltd. deal**

BioChem Solutions signs \$25M VitaPro International Ltd. deal

Frankfurt, Germany -- BioChem Solutions Inc. today announced execution of a Licensing Agreement valued at USD \$25 million with VitaPro International Ltd. of Nassau, Bahamas.

The agreement calls for VitaPro to acquire a Master License from BioChem Solutions Inc. to exclusively manufacture market and distribute the BioChem product "Arthromir" worldwide. A copy of the license agreement can be viewed at [www.biochemsolutionsinc.com](http://www.biochemsolutionsinc.com) under Media, Press & Related articles.

VitaPro will secure regulatory authorization to manufacture, distribute and sell BioChem Solutions product "Arthromir". In medical trials to date, the product has shown significant improvement in the function of the human immune system, particularly with regard to rheumatoid arthritis.

VitaPro, a major producer of a soya based meat replacement with headquarters in the Nassau, Bahamas, will acquire a worldwide license to produce, sell and distribute "Arthromir" according to terms of the agreement VitaPro will over the next ninety days provide the BioChem board of director's marketing plan, for approval and implementation. For more information on VitaPro please visit their web site [www.vitapro.com](http://www.vitapro.com).

Upon closing the transaction, VitaPro will be authorized to manufacture market and distribute BioChem Solutions product Arthromir Worldwide. Founded more than a decade ago, VitaPro is a leading producer of soya based meat replacement products using their proprietary recipes and formulas. VitaPro has pioneered breakthrough soya protein food products that fill the need for an appetizing substitute for meat protein at a fraction of the cost that does not sacrifice flavor and texture for nutritional value.

"This is an exciting and important alliance with one of the most respected soya based food manufacturers," said Michael Gomez, BioChem Solutions Inc. president. "We look forward to this new relationship with VitaPro, and its affiliates".

BioChem Solutions holds the worldwide patent for the Trioxolane, Diperoxide compound the active ingredient in Arthromir.

BioChem Solutions also holds the global master license to produce and market medications derived from the patented product Diperoxide. In trials to date, both Trioxolane and Diperoxide derivatives have shown significant improvement in the function of the human immune system using a variety of indicators.

The use of these derivatives has potential in destroying tumor cells and harmful micro-organisms such as bacteria, viruses, parasites and fungi. Treatment is non-toxic and has shown no adverse side effects. Moreover, these products reinforce natural immune systems in combating harmful agents and regulating the beneficial production of serotonin, prostaglandin and inflammatory interleukins.

Company representatives are exploring the many opportunities for commercial development of its

patented products and potential business alliances.

### 30 ###

Company Contact: [www.biochemsolutionsinc.com](http://www.biochemsolutionsinc.com) -- [info@biochemsolutionsinc.com](mailto:info@biochemsolutionsinc.com)  
U.S. Telephone: (305) 423-7108 Fax: (305) 908-7601

Investor Relations UK: Sterling Davis International  
James Richardson Managing Director -- [info@sterlingdavisintl.com](mailto:info@sterlingdavisintl.com)  
U.K. Telephone: +448458340737

Investor Relations E.U.: Matilix Systems Inc.  
Mr. Larry Brenhouse – [larrybrenhouse@yahoo.ca](mailto:larrybrenhouse@yahoo.ca)  
PHONE: +34 622 033 747

Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The company's actual results could differ materially from those anticipated in the forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.

**NEWSLETTER REGISTRIERUNG:**

Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:  
[http://www.irw-press.com/alert\\_subscription.php?lang=en&isin=US0909651046](http://www.irw-press.com/alert_subscription.php?lang=en&isin=US0909651046)

Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender verantwortlich.  
Kostenloser Abdruck mit Quellenangabe erlaubt.